Cellular platforms for HTS: three case studies.
The field of cell-based screening is expanding rapidly as innovations in target selection and instrumentation increase the number of targets that can be efficiently screened in cellular formats. Cell-based screens can be configured to provide a broad range of data on chemical compound activity, mechanism of action and drugability. However, the decision to pursue a cell-based approach should not be made lightly, as cell-based assays can be challenging to implement in the high-throughput screening (HTS) laboratory. In this review, we describe three case studies in which targets were successfully interrogated in cell-based HTS, and highlight the necessary steps to ensure the validity of these screens.
Johnston
Paul A
PA
Sphinx Laboratories, Lilly Research Laboratories, A Division of Eli Lilly and Company, 20 T.W. Alexander Drive, PO Box 13951, Research Triangle Park, NC 27709, USA.
Johnston
Patricia A
PA
D000818:Animals; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism; D002478:Cells, Cultured; D003584:Cytological Techniques; D004353:Drug Evaluation, Preclinical / Q000191:economics / Q000639:trends*; D006801:Humans; D008156:Luciferases / Q000235:genetics; D010600:Pharmacology / Q000639:trends; D019275:Radiopharmaceuticals / Q000737:chemistry; D015203:Reproducibility of Results
D002352:Carrier Proteins; D019275:Radiopharmaceuticals; D008156:Luciferases